IBL-302 (AMU302) is an orally active dual inhibitor of PIM and PI3K/AKT/mTOR signaling pathways, exhibiting anti-breast cancer and anti-neuroblastoma activities; it demonstrates in vivo efficacy in nude mouse xenograft models and overcomes trastuzumab (HY-P9907) resistance; additionally, it enhances the efficacy of common cytotoxic chemotherapeutic agents such as cisplatin (HY-17394), doxorubicin (HY-15142A), and etoposide (HY-13629).